Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLI5VH)

Drug Name

MDL 100,453 Drug Info

Synonyms

D-Norvaline, 4-oxo-5-phosphono-; CHEMBL431029; MDL-100483; 129938-34-7; 4-Opnv; Mdl 100453; 4-Oxo-5-phosphononorvaline; AC1MHZND; SCHEMBL195547; (r)-4-oxo-5-phosphononorvaline; BDBM50010893; AKOS030593176; MDL-100453; 2-Amino-4-oxo-5-phosphono-pentanoic acid; (2R)-2-amino-4-oxo-5-phosphonopentanoic acid; (R)-2-Amino-4-oxo-5-phosphono-pentanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 3035602
CAS Number: CAS 129938-34-7
TTD Drug ID: DMLI5VH

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glutamate receptor ionotropic NMDA 2A (NMDAR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glycine	DMIOZ29	Allergic rhinitis	CA08.0	Approved	[2]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[3]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[4]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[5]
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[6]
L-698544	DMLRBN1	Alzheimer disease	8A20	Terminated	[7]
DIZOCILPINE	DMMGYXR	Cerebrovascular ischaemia	8B1Z	Terminated	[8]
RPR-104632	DM9L50N	N. A.	N. A.	Terminated	[9]
L-698532	DMO9HM7	Neurological disorder	6B60	Terminated	[10]
L-695902	DMT1DNS	N. A.	N. A.	Terminated	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor ionotropic NMDA 2A (NMDAR2A)	TTKJEMQ	NMDE1_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther. 1999 Sep;290(3):1034-40.
2	Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78.
3	Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
4	4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
5	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
7	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
8	Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
9	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
10	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.